In this video, Leo Rasche, MD, University of Würzburg, Würzburg, Germany, discusses a recent study in which whole-genome sequencing (WGS) data demonstrated a loss of BCMA and GPRC5D in patients with relapsed/refractory (R/R) multiple myeloma treated with bispecific antibodies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.